**Supplementary 1. Baseline characteristics between the two groups for all patients. (\*p < 0.05; \*\*p < 0.01; and \*\*\*p < 0.001)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Overall**  **N=748** | **Adjuvant chemotherapy**  **N=59** | **Observation**  **N=689** | **P-value** |
| **Age** |  |  |  | - |
| Mean (SD) | 71.2 (10.3) | 67.0 (8.9) | 71.6 (10.4) |  |
| Median  [Min, Max] | 72.0  [41.0,94.0] | 68.0  [48.0,82.0] | 73.0  [41.0,94.0] |  |
| **Gender** |  |  |  | 0.924 |
| Female | 201 (26.9) | 15 (25.4) | 186 (27.0) |  |
| Male | 546 (73.0) | 44 (74.6) | 502 (72.9) |  |
| Missing | 1 (0.1) | - | 1 (0.1) |  |
| **Smoking Status** |  |  |  | 0.264 |
| Current smoker | 206 (27.5) | 12 (20.3) | 194 (28.2) |  |
| Ex-smoker | 259 (34.6) | 22 (37.3) | 237 (34.4) |  |
| Nonsmoker | 216 (28.9) | 22 (37.3) | 194 (28.2) |  |
| Missing | 67 (9.0) | 3 (5.1) | 64 (9.3) |  |
| **CCI** |  |  |  | 0.321 |
| 0-1 | 289 (38.6) | 23 (39.0) | 266 (38.6) |  |
| ≥2 | 259 (34.6) | 16 (27.1) | 243 (35.3) |  |
| Missing | 200 (26.7) | 20 (33.9) | 180 (26.1) |  |
| **pT Stage** |  |  |  | <0.001\*\*\* |
| Ta/Tis/T1 | 329 (44.0) | 4 (6.8) | 325 (47.2) |  |
| T2 | 153 (20.5) | 8 (13.6) | 145 (21.0) |  |
| T3 | 240 (32.1) | 40 (67.8) | 200 (29.0) |  |
| T4 | 26 (3.5) | 7 (11.9) | 19 (2.8) |  |
| Missing | - | - | - |  |
| **Tumor Grade** |  |  |  | <0.001\*\*\* |
| G1 | 101 (13.5) | 2 (3.4) | 99 (14.4) |  |
| G2 | 189 (25.3) | 4 (6.8) | 185 (26.9) |  |
| G3 | 453 (60.6) | 53 (89.8) | 400 (58.1) |  |
| GX | 5 (0.7) | - | 5 (0.7) |  |
| **Chemotherapy regimen** |  |  |  | - |
| Gemcitabine |  | 32 | - |  |
| MVAC |  | 5 | - |  |
| Gemcitabine+Cisplatin |  | 14 | - |  |
| Gemcitabine+Carboplatin |  | 2 | - |  |
| Gemcitabine+BDCA |  | 1 | - |  |
| Gemcitabine+DTX  +Cisplatin |  | 1 | - |  |
| Others |  | 6 | - |  |

CCI: Charlson Comorbidity Index;

MVAC: methotrexate + vinblastine sulfate + Adriamycin + cisplatin

**Supplementary 2. Baseline characteristics of overall patients.**

|  |  |
| --- | --- |
|  | **Overall**  **N=2380** |
| **Age** |  |
| Mean (SD) | 71.4 (10.6) |
| Median  [Min, Max] | 73.0  [35.0,94.0] |
| **Gender** |  |
| Female | 697 (29.3) |
| Male | 1677 (70.5) |
| Missing | 6 (0.2) |
| **Smoking Status** |  |
| Current smoker | 572 (24.0) |
| Ex-smoker | 696 (29.2) |
| Nonsmoker | 684 (28.7) |
| Missing | 428 (18.1) |
| **CCI** |  |
| 0-1 | 825 (34.7) |
| ≥2 | 774 (32.5) |
| Missing | 781 (32.8) |
| **pT Stage** |  |
| Ta/Tis/T1 | 840 (35.3) |
| T2 | 442 (18.6) |
| T3 | 296 (12.4) |
| T4 | 63 (2.6) |
| Missing | 739 (31.0) |
| **Tumor Grade** |  |
| G1 | 329 (13.8) |
| G2 | 430 (18.1) |
| G3 | 839 (35.2) |
| GX | 22 (0.9) |
| Missing | 760 (32.0) |
| **Tumor Recurrence** |  |
| Yes | 446 (18.7) |
| No | 865 (36.3) |
| Missing | 1069 (45.0) |

**Supplementary 3. Comparison of recurrence-free survival between patients (A) received gemcitabine monotherapy or platinum-containing chemotherapy, and (B) received gemcitabine monotherapy or observation.**

A)

Rplot

B)

Rplot01